CN107580595B - 杂环化合物及它们在预防或治疗细菌感染中的应用 - Google Patents

杂环化合物及它们在预防或治疗细菌感染中的应用 Download PDF

Info

Publication number
CN107580595B
CN107580595B CN201680026527.9A CN201680026527A CN107580595B CN 107580595 B CN107580595 B CN 107580595B CN 201680026527 A CN201680026527 A CN 201680026527A CN 107580595 B CN107580595 B CN 107580595B
Authority
CN
China
Prior art keywords
mmol
oxo
oct
diazabicyclo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680026527.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107580595A (zh
Inventor
朱利安·巴比欧
奥德丽·卡拉瓦诺
索菲·查赛特
弗朗西斯·切弗勒依
尼古拉·莱科因特
伯诺瓦·勒杜萨尔
弗雷德里克·勒斯塔特
塞巴斯蒂安·理查德
克利斯朵夫·西蒙
苏菲·沃米思德
朱莉·布利亚
索菲娅·布里埃特
法比安·费弗尔
杰拉尔丁·勒弗拉里克
克里斯泰·奥利韦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mutabilis SA
Original Assignee
Mutabilis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15305701.3A external-priority patent/EP3091018A1/en
Application filed by Mutabilis SA filed Critical Mutabilis SA
Publication of CN107580595A publication Critical patent/CN107580595A/zh
Application granted granted Critical
Publication of CN107580595B publication Critical patent/CN107580595B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680026527.9A 2015-05-07 2016-05-06 杂环化合物及它们在预防或治疗细菌感染中的应用 Active CN107580595B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15305701.3A EP3091018A1 (en) 2015-05-07 2015-05-07 Heterocyclic compounds and their use in preventing or treating bacterial infections
EP15305701.3 2015-05-07
EP16305144 2016-02-08
EP16305144.4 2016-02-08
PCT/EP2016/060142 WO2016177862A1 (en) 2015-05-07 2016-05-06 Heterocyclic compounds and their use in preventing or treating bacterial infections

Publications (2)

Publication Number Publication Date
CN107580595A CN107580595A (zh) 2018-01-12
CN107580595B true CN107580595B (zh) 2020-09-18

Family

ID=56083989

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680026527.9A Active CN107580595B (zh) 2015-05-07 2016-05-06 杂环化合物及它们在预防或治疗细菌感染中的应用

Country Status (13)

Country Link
US (1) US10183943B2 (enExample)
EP (1) EP3292125B1 (enExample)
JP (1) JP6767392B2 (enExample)
KR (1) KR102713561B1 (enExample)
CN (1) CN107580595B (enExample)
AU (1) AU2016257338B2 (enExample)
BR (1) BR112017023359A2 (enExample)
CA (1) CA2983674A1 (enExample)
CL (1) CL2017002803A1 (enExample)
MX (1) MX2017014080A (enExample)
RU (1) RU2741496C2 (enExample)
TW (1) TWI754613B (enExample)
WO (1) WO2016177862A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170014135A1 (en) 2015-07-14 2017-01-19 Keith Edward Martin Surgical tool
EP3300736B1 (en) * 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
ES2960952T3 (es) 2018-08-09 2024-03-07 Antabio Sas Diazabiciclooctanonas como inhibidores de serina beta-lactamasas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010172A1 (fr) * 2000-08-01 2002-02-07 Aventis Pharma Sa Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
WO2013150296A1 (en) * 2012-04-02 2013-10-10 Astrazeneca Ab Heterobicyclic compounds as beta-lactamase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
EP2231667B1 (en) * 2008-01-18 2013-09-04 Merck Sharp & Dohme Corp. Beta-lactamase inhibitors
BR112013032974A2 (pt) * 2011-08-30 2016-09-06 Wockhardt Ltd "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
SG11201406123TA (en) * 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
CN104470906B (zh) 2012-06-04 2016-08-24 爱尔克米亚 作为抵抗紫外线辐射的保护剂的亚氨基化合物
US20140315876A1 (en) * 2013-03-15 2014-10-23 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
BR112016008979B1 (pt) * 2013-10-22 2023-04-25 Wockhardt Limited Composições farmacêuticas compreendendo agentes antibacterianos e seus usos
KR20170132301A (ko) * 2015-03-31 2017-12-01 무타빌리스 신규한 헤테로사이클릭 화합물들 및 세균성 감염의 예방 또는 치료에서 그들의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010172A1 (fr) * 2000-08-01 2002-02-07 Aventis Pharma Sa Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
WO2013150296A1 (en) * 2012-04-02 2013-10-10 Astrazeneca Ab Heterobicyclic compounds as beta-lactamase inhibitors

Also Published As

Publication number Publication date
US20180093985A1 (en) 2018-04-05
KR102713561B1 (ko) 2024-10-08
TWI754613B (zh) 2022-02-11
AU2016257338A1 (en) 2017-10-26
RU2017135321A3 (enExample) 2019-08-13
AU2016257338B2 (en) 2020-03-05
BR112017023359A2 (pt) 2018-07-17
EP3292125B1 (en) 2019-09-04
KR20180002650A (ko) 2018-01-08
CL2017002803A1 (es) 2018-05-11
RU2741496C2 (ru) 2021-01-26
NZ736152A (en) 2024-09-27
WO2016177862A1 (en) 2016-11-10
MX2017014080A (es) 2018-07-06
CN107580595A (zh) 2018-01-12
RU2017135321A (ru) 2019-04-10
US10183943B2 (en) 2019-01-22
JP2018515504A (ja) 2018-06-14
JP6767392B2 (ja) 2020-10-14
EP3292125A1 (en) 2018-03-14
TW201643165A (zh) 2016-12-16
CA2983674A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
JP7281527B2 (ja) ベータラクタマーゼ阻害剤化合物
CN107580595B (zh) 杂环化合物及它们在预防或治疗细菌感染中的应用
TWI736517B (zh) 作為抗癌劑之新穎三環化合物
CN109906226B (zh) 杂环化合物及它们在预防或治疗细菌感染中的应用
EP3300736B1 (en) Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
CN107438614A (zh) 杂环化合物及它们在预防或治疗细菌感染中的应用
CN107531708A (zh) 新型杂环化合物及它们在预防或治疗细菌感染中的应用
CN113272302A (zh) 抗生素化合物、其制造方法、包含其的药物组合物及其用途
CN107438610A (zh) 杂环化合物及它们在预防或治疗细菌感染中的应用
CN112513049A (zh) 杂环化合物及它们在预防或治疗细菌感染中的用途
EP3091018A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
CN107922436A (zh) 具有亚磺酰基或磺酰基的三环性化合物
HK40002917B (zh) 杂环化合物及它们在预防或治疗细菌感染中的应用
HK40002917A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
EA044428B1 (ru) Соединения-ингибиторы бета-лактамаз
HK1241877A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant